379 related articles for article (PubMed ID: 27378171)
1. Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
DiBardino DM; Saqi A; Elvin JA; Greenbowe J; Suh JH; Miller VA; Ali SM; Stoopler M; Bulman WA
Clin Lung Cancer; 2016 Nov; 17(6):517-522.e3. PubMed ID: 27378171
[TBL] [Abstract][Full Text] [Related]
2. Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Youssef O; Knuuttila A; Piirilä P; Böhling T; Sarhadi V; Knuutila S
Anticancer Res; 2018 Oct; 38(10):5627-5634. PubMed ID: 30275180
[TBL] [Abstract][Full Text] [Related]
3. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS
Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923
[TBL] [Abstract][Full Text] [Related]
4. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
[TBL] [Abstract][Full Text] [Related]
5. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
6. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
7. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
[TBL] [Abstract][Full Text] [Related]
8. Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.
Bar J; Damianovich M; Hout Siloni G; Dar E; Cohen Y; Perelman M; Ben Nun A; Simansky D; Yellin A; Urban D; Onn A
Clin Lung Cancer; 2014 Mar; 15(2):159-65. PubMed ID: 24370118
[TBL] [Abstract][Full Text] [Related]
9. Clinical next-generation sequencing in patients with non-small cell lung cancer.
Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
[TBL] [Abstract][Full Text] [Related]
10. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
[TBL] [Abstract][Full Text] [Related]
11. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
Fumagalli C; Vacirca D; Rappa A; Passaro A; Guarize J; Rafaniello Raviele P; de Marinis F; Spaggiari L; Casadio C; Viale G; Barberis M; Guerini-Rocco E
J Clin Pathol; 2018 Sep; 71(9):767-773. PubMed ID: 29535211
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of next-generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma.
Baum JE; Zhang P; Hoda RS; Geraghty B; Rennert H; Narula N; Fernandes HD
Cancer Cytopathol; 2017 Jun; 125(6):398-406. PubMed ID: 28272845
[TBL] [Abstract][Full Text] [Related]
13. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
[TBL] [Abstract][Full Text] [Related]
15. Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication.
Rafael OC; Aziz M; Raftopoulos H; Vele OE; Xu W; Sugrue C
Cancer Cytopathol; 2014 Jun; 122(6):454-8. PubMed ID: 24723383
[TBL] [Abstract][Full Text] [Related]
16. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
[TBL] [Abstract][Full Text] [Related]
17. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
Driver BR; Portier BP; Mody DR; Deavers M; Bernicker EH; Kim MP; Teh BS; Santacruz JF; Kopas L; Munden RF; Cagle PT
Arch Pathol Lab Med; 2016 Apr; 140(4):312-7. PubMed ID: 26430808
[TBL] [Abstract][Full Text] [Related]
18. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
19. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer.
Mao X; Zhang Z; Zheng X; Xie F; Duan F; Jiang L; Chuai S; Han-Zhang H; Han B; Sun J
J Thorac Oncol; 2017 Apr; 12(4):663-672. PubMed ID: 28007624
[TBL] [Abstract][Full Text] [Related]
20. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.
Treece AL; Montgomery ND; Patel NM; Civalier CJ; Dodd LG; Gulley ML; Booker JK; Weck KE
Cancer Cytopathol; 2016 Jun; 124(6):406-14. PubMed ID: 26882436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
